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C ase Presentation:
A 68-year-old woman with hypertension, diabetes mellitus, and congestive heart failure presented to the emergency department with palpitations. On physical examination, her heart rate was 130 bpm and irregularly irregular, her blood pressure was 120/70 mm Hg, and she weighed 60 kg. The ECG demonstrated atrial fibrillation (AF) with a rapid ventricular rate. Laboratory evaluation was remarkable for a serum creatinine of 1.3 mg/dL. Her symptoms resolved with heart rate control.
Background
AF is the most common arrhythmia in patients with chronic kidney disease (CKD) and is associated with increased risk of stroke and thromboembolism. The risk of stroke increases as renal function declines. Conversely, patients with CKD, particularly those on hemodialysis, are at an increased risk of bleeding. Oral anticoagulation is the most effective form of thromboprophylaxis in patients with AF at increased risk of stroke. Concern for bleeding has resulted in the underuse of anticoagulation in these patients. 
Warfarin in AF With CKD
No large, randomized, controlled trial has studied the role of warfarin in preventing stroke in patients with AF specifically with severe renal impairment. Some studies have reported a reduced risk of stroke, whereas others found no difference or even increased risk of stroke with warfarin in CKD. As with any observational analysis, these studies have several limitations resulting from residual confounding, and the associations found may not be causal. One study of 132 372 patients with AF in Denmark demonstrated that warfarin compared with no antithrombotic therapy resulted in a lower incidence of stroke in patients with CKD, including those on dialysis. 2 The authors found that warfarin compared with no antithrombotic therapy was associated with a higher risk of bleeding in patients with CKD. Similarly, among patients with AF, CKD, and myocardial infarction in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry, treatment with warfarin compared with no anticoagulation reduced all-cause mortality, recurrent myocardial infarction, and stroke without an increased risk of bleeding. 3 A recent analysis of 154 259 patients from Danish national registries found warfarin to be beneficial for stroke prevention in patients with CKD. 1 This study showed lower risks of all-cause mortality, cardiovascular death, and a composite of fatal stroke or fatal bleeding with warfarin compared with no antithrombotic therapy in patients with CKD. Additionally, the investigators found no increased risk of hemorrhagic stroke or major bleeding with warfarin.
Contrary to these findings, a retrospective analysis of 205 836 patients with CKD in Canada demonstrated a higher risk of bleeding with warfarin compared with no warfarin. However, this study showed a reduced risk of stroke with warfarin compared with no warfarin. 4 Furthermore, a retrospective study of 1671 patients on dialysis in the United States and Canada reported an increased risk of stroke with warfarin versus no antithrombotic therapy. 5 In this cohort, the risk of stroke was highest in patients who did not undergo routine monitoring of anticoagulation with the international normalized ratio.
Warfarin treatment in AF patients with CKD presents additional risks that are less common in the non-CKD population. Warfarin is associated with an increased risk of vascular calcification, calciphylaxis, and access site bleeding in dialysis patients. 
NOACs in AF With CKD
NOACs have emerged as a promising alternative to warfarin for the prevention of stroke and systemic thromboembolism in patients with AF. Unlike warfarin, NOACs have a predictable effect without the need for frequent monitoring and have fewer diet and drug interactions. The pharmacokinetic profile of each NOAC is unique and should be taken into consideration in the selection of an antithrombotic therapy for patients with AF (Table 1) . 7 All NOACs undergo some degree of renal clearance; as a consequence, the risk of bleeding increases with deterioration of renal function. Dose modification is recommended in patients with reduced renal function ( Table 2) .
Contemporary trials of apixaban, dabigatran, edoxaban, and rivaroxaban showed efficacy and safety that were comparable or superior to those of warfarin in patients with AF and moderate CKD (eCrCl, 30-49 mL·min Figure) . [8] [9] [10] [11] [12] The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial demonstrated that apixaban compared with warfarin was associated with a lower risk of stroke, thromboembolism, major bleeding, and death in patients with moderate CKD. 9 Similarly, in the RE-LY trial, dabigatran was superior to warfarin in patients with ‡Not recommended in patients with eCrCl >95 mL/min.
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moderate CKD in preventing stroke and thromboembolism. 10 In patients with moderate CKD in the Effective Anticoagulation With Factor Xa Next Generation in Atrial FibrillationThrombolysis in Myocardial Infarction 48 (ENGAGE-AF TIMI 48) trial, edoxaban compared with warfarin showed similar efficacy in preventing stroke and a lower risk of bleeding and cardiovascular death. 11 In agreement with previous studies, the Rivaroxaban OnceDaily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial demonstrated a trend toward lower risk of stroke, thromboembolism, and fatal bleeding with rivaroxaban compared with warfarin in the subgroup with moderate CKD. 12 Overall, these findings suggest that in patients with moderate CKD, NOACs have a favorable net clinical benefit.
None of the NOACs have been well studied in patients with AF who are on dialysis or have eCrCl <30 mL·min . Dabigatran, edoxaban, and rivaroxaban are not approved for use in patients on dialysis. Apixaban is approved on the basis of pharmacokinetic data. In a retrospective analysis of 29 977 patients with AF on hemodialysis in the United States, Chan et al 13 found dabigatran or rivaroxaban to be associated with an increased risk of hospitalization or death resulting from bleeding compared with warfarin. ) and those on dialysis. Until then, in the absence of major contraindications, warfarin with careful international normalized ratio monitoring should generally be prescribed in patients with AF and severe renal impairment, including those on dialysis, although apixaban is an approved option.
Summary and Management of Presented Case
Our patient represents a patient with AF with moderate CKD. Despite her modest creatinine elevation, her eCrCl calculates to 39.2 mL/min, underscoring the importance of not basing decisions on creatinine alone. Her annual stroke risk is 6.7% based on a CHA 2 DS 2 -VASc score of 5. We recommended anticoagulation with apixaban 5 mg twice daily for the prevention of stroke and systemic embolism, with a plan for close monitoring of her renal function. We chose apixaban because of the lower risk of bleeding compared with warfarin. 9 Thromboprophylaxis with adjusted dosing of dabigatran, edoxaban, or rivaroxaban or with warfarin would also have been reasonable. 
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